Decoding the Language
of Life
Harnessing advanced analytical technology and AI to unravel disease and aging at the molecular level, developing earlier diagnostics and truly effective health solutions
One Core, Three Wings
Advanced analytical technology at the center, three business pillars empowering each other to build a complete chain from drug R&D to health management
ShangXi's core competitiveness stems from our founding team's 20+ years of analytical method development expertise. Leveraging cutting-edge technologies including LC-MS/MS and GC-MS/MS, combined with AI-driven data analytics, we precisely decode compound structures, drug metabolism pathways, and disease biomarkers at the molecular level. This core technology platform — the 'One Core' — powers our three business pillars: CRO Analytical Services, Early Disease Diagnosis, and Anti-Aging & Health Management — the 'Three Wings' flying in formation.
CRO Analytical Services
With 20+ years of GLP/GMP compliance expertise, we provide end-to-end analytical support from drug discovery through clinical trials. Services include: generic drug bioequivalence studies, advanced method development & validation, pharmacokinetics, impurity profiling, and more. We have served 150+ pharmaceutical companies globally, developing and validating 100+ analytical methods — all meeting or exceeding industry publication standards.
Early Disease Diagnosis
Focusing on major chronic diseases including Alzheimer's, cancer, cardiovascular disease, and diabetes, we leverage high-sensitivity analytical technology combined with AI algorithms to identify early disease biomarkers from biofluids. Our goal: develop diagnostic methods that detect disease 3-5 years earlier than current standards — more accurate, more accessible, and more affordable — enabling intervention while conditions remain reversible.
Anti-Aging & Health Management
Decoding aging mechanisms at the molecular level, we translate our analytical expertise into consumer-facing health products. Developing functional skincare (based on transdermal absorption analysis), oral supplements (bioavailability-optimized formulations), and personalized dynamic health assessment services. Every product carries the 'From ShangXi Labs' promise — efficacy backed by scientific data, distinctly different from evidence-lacking generic supplements on the market.
More capabilities coming soon
R&D Pipeline
Class 2 Modified New Drugs via FDA 505(b)(2) Pathway — The Optimal Balance of Innovation and Efficiency
The 505(b)(2) NDA pathway is the FDA's regulatory route for modified new drugs. Compared to developing a completely new chemical entity (averaging 10 years, $1-1.5 billion, ~10% success rate), the 505(b)(2) pathway leverages existing safety and pharmacology data of known active ingredients, achieving clinical advantage through formulation innovation, delivery route optimization, or indication expansion — reducing development to 3-5 years, cost to $80-200 million, and boosting success rates to 50-60%. ShangXi chose this pathway based on our team's deep expertise in analytical chemistry and formulation science, combined with precise market demand assessment.
Pipeline details are being updated. Stay tuned.
Why 505(b)(2)
| 505(b)(2) | New Chemical Entity | |
|---|---|---|
| Development Timeline | 3-5 Years | 10-15 Years |
| Development Cost | $80-200M | $1-1.5B |
| Success Rate | 50-60% | ~10% |
| Market Exclusivity | 3-7 Years | 5-7 Years |
Core Team
Bringing together world-class expertise in biomedical engineering, analytical chemistry, AI, and business operations
Team member info coming soon
Team member info coming soon
Team member info coming soon
Team member info coming soon
Trusted by Partners
Collaborations with leading institutions worldwide
Partner with Us in Decoding Life
Whether you're a pharmaceutical company seeking CRO collaboration, an investor exploring biotech opportunities, or a research institution pursuing technology translation — we welcome your inquiry
Careers Email
hr@sxyxcn.com